FUNCTIONAL AREAS – Page 33

Excipient variability impact during pilot scale – CAPA during development lifecycle

The first step in addressing excipient variability is recognizing the symptoms or signals indicative of potential issues. Symptoms can manifest on the floor during production or in the laboratories responsible…

Formulation robustness underestimated during early development – data package improvements for filing

Identifying early warning signals regarding formulation robustness is crucial in minimizing downstream impacts. Common symptoms may include:Click to read the full article.

Method development instability during comparability assessment – how to ensure smooth tech transfer

Recognition of symptoms indicative of method development instability is the first step in addressing the issue. Symptoms may manifest as:Click to read the full article.

Formulation robustness underestimated during scale-up – data package improvements for filing

Identifying symptoms or signals that indicate formulation robustness might be compromised is critical for timely investigations. Common indicators include:Click to read the full article.

Method development instability during comparability assessment – regulatory scrutiny implications

Recognizing symptoms of method development instability is crucial for early intervention. This instability may manifest in various forms during comparability assessments:Click to read the full article.

Tech transfer readiness gaps during transfer to manufacturing – data package improvements for filing

Effective communication among team members is essential for early detection of tech transfer readiness gaps. Symptoms can manifest in various forms, including:Click to read the full article.

Design space poorly justified during early development – how to ensure smooth tech transfer

Identifying anomalies early is critical in maintaining product integrity and compliance during the development phase. The symptoms associated with a poorly justified design space can manifest in various ways:Click to…

Process knowledge not captured during transfer to manufacturing – CAPA during development lifecycle

Identifying early signals of inadequate process knowledge transfer is essential for timely intervention. Common symptoms may include:Click to read the full article.

Method development instability during comparability assessment – downstream GMP risk and prevention

Recognition of instability in method development during a comparability assessment is critical in validating drug products. Symptoms can manifest in various ways, including:Click to read the full article.

Scale-up risk not identified during pilot scale – downstream GMP risk and prevention

Early recognition of symptoms or signals is essential in mitigating scale-up risks. Inadequate signaling can result in severe implications, including product quality issues or regulatory citations. The following symptoms typically…

Process knowledge not captured during comparability assessment – downstream GMP risk and prevention

Identifying the symptoms and signals of inadequate process knowledge is the first step in addressing the risks involved. Common signs include:Click to read the full article.

Excipient variability impact during scale-up – regulatory scrutiny implications

Identifying symptoms of excipient variability is crucial during scale-up. These symptoms can manifest in various ways, including:Click to read the full article.